Overcoming obstacles in microRNA delivery towards improved cancer therapy

Drug Delivery and Translational Research

Volumn 4, Issue 1, 2014, Pages 38-49

  Ben Shushan, Dikla ^a   Markovsky, Ela ^a   Gibori, Hadas ^a   Tiram, Galia ^a   Scomparin, Anna ^a   Satchi Fainaro, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer therapeutics; Combination therapy; Drug delivery systems; RNAi

Indexed keywords

GOLD NANOPARTICLE; LIPOSOME; MICRORNA; NANOCARRIER; NANOPARTICLE; POLYGLACTIN; POLYMER; SILICA NANOPARTICLE; UNCLASSIFIED DRUG;

BIOGENESIS; CANCER GENE THERAPY; COMPLEX FORMATION; CONJUGATION; GENE TARGETING; HUMAN; IMMUNOGENICITY; KIDNEY CLEARANCE; LIPID VESICLE; MALIGNANT NEOPLASTIC DISEASE; NANOENCAPSULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; RNA DEGRADATION; RNA INTERFERENCE;

EID: 84893529322     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-013-0160-0     Document Type: Review

References (87)

1. Tiram G, Scomparin A, Ofek P, Satchi-Fainaro R. Interfering cancer with polymeric siRNA nanocarriers. J Biomed Nanotechnol. 2013; in press.
2. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001;409(6818): 363-6.
3. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell. 2000;101(1): 25-33.
4. Ahlquist P. RNA-dependent RNA, polymerases, viruses, and RNA silencing. Science. 2002;296(5571): 1270-3.
5. Zeng Y, Yi R, Cullen BR. Recognition and cleavage of primary microRNA precursors by the nuclear processing enzyme Drosha. EMBO J. 2005;24(1): 138-48.
6. Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development. 2005;132(21): 4653-62.
7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2): 281-97.
8. Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol. 2007;23: 175-205.
9. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther. 2006;13(6): 496-502.
10. Lee YS, Kim HK, Chung S, Kim KS, Dutta A. Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J Biol Chem. 2005;280(17): 16635-41.
11. Esau CC. Inhibition of microRNA with antisense oligonucleotides. Methods. 2008;44(1): 55-60.
12. Henry JC, Azevedo-Pouly AC, Schmittgen TD. MicroRNA replacement therapy for cancer. Pharm Res. 2011;28(12): 3030-42.
13. Ramachandran PV, Ignacimuthu S. RNA interference as a plausible anticancer therapeutic tool. Asian Pac J Cancer Prev. 2012;13(6): 2445-52.
14. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26(4): 462-9.
15. Esau CC, Monia BP. Therapeutic potential for microRNAs. Adv Drug Deliv Rev. 2007;59(2-3): 101-14.
16. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4): 259-69.
17. Kim E, Yang J, Park J, Kim S, Kim NH, Yook JI, et al. Consecutive targetable smart nanoprobe for molecular recognition of cytoplasmic microRNA in metastatic breast cancer. ACS Nano. 2012;6(10): 8525-35.
18. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101(9): 2999-3004.
19. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11): 857-66.
20. He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer. 2007;7(11): 819-22.
21. Almog N, Ma L, Schwager C, Brinkmann BG, Beheshti A, Vajkoczy P, et al. Consensus micro RNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype. PLoS One. 2012;7(8): e44001.
22. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21): 1182-6.
23. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 2006;38(9): 1060-5.
24. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One. 2006;1: e116.
25. Ferracin M, Pedriali M, Veronese A, Zagatti B, Gafa R, Magri E, et al. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol. 2011;225(1): 43-53.
26. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012;6(6): 590-610.
27. Scomparin A, Tiram G, Satchi-Fainaro R. Nanoscale-based delivery of RNAi for cancer therapy. In: Erdmann VA, Barciszewski J, editors. DNA and RNA nanotechnologies in medicine. Diagnosis and treatment of diseases. Berlin: Springer; 2013.
28. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303(5663): 1529-31.
29. Robbins M, Judge A, Liang L, McClintock K, Yaworski E, MacLachlan I. 2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther. 2007;15(9): 1663-9.
30. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence. 2012;3(1): 1.
31. Lennox KA, Behlke MA. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 2011;18(12): 1111-20.
32. Davis S, Lollo B, Freier S, Esau C. Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res. 2006;34(8): 2294-304.
33. Li L, Shen Y. Overcoming obstacles to develop effective and safe siRNA therapeutics. Expert Opin Biol Ther. 2009;9(5): 609-19.
34. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2(3): 214-21.
35. Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther. 2005;312(3): 1020-6.
36. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1): 6387-92.
37. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4): 505-15.
38. Markovsky E, Baabur-Cohen H, Eldar-Boock A, Omer L, Tiram G, Ferber S, et al. Administration, distribution, metabolism and elimination of polymer therapeutics. J Control Release. 2012;161(2): 446-60.
39. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009;9(5): 1909-15.
40. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66(13): 6732-40.
41. Brasnjevic I, Steinbusch HW, Schmitz C, Martinez-Martinez P. Delivery of peptide and protein drugs over the blood-brain barrier. Prog Neurobiol. 2009;87(4): 212-51.
42. Cryan SA. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J. 2005;7(1): E20-41.
43. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A. 1995;92(16): 7297-301.
44. Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci. 2010;123(Pt 8): 1183-9.
45. Huang HW, Chen FY, Lee MT. Molecular mechanism of peptide-induced pores in membranes. Phys Rev Lett. 2004;92(19): 198304.
46. Hafez IM, Maurer N, Cullis PR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 2001;8(15): 1188-96.
47. Olejniczak M, Galka P, Krzyzosiak WJ. Sequence-non-specific effects of RNA interference triggers and microRNA regulators. Nucleic Acids Res. 2010;38(1): 1-16.
48. Zelphati O, Szoka Jr FC. Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci U S A. 1996;93(21): 11493-8.
49. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108(12): 5003-8.
50. Doh KO, Yeo Y. Application of polysaccharides for surface modification of nanomedicines. Ther Deliv. 2012;3(12): 1447-56.
51. Peer D, Florentin A, Margalit R. Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. Biochim Biophys Acta. 2003;1612(1): 76-82.
52. Wu Y, Crawford M, Mao Y, Lee RJ, Davis IC, Elton TS, et al. Therapeutic delivery of MicroRNA-29b by cationic lipoplexes for lung cancer. Mol Ther Nucleic Acids. 2013;2: e84.
53. Wu Y, Crawford M, Yu B, Mao Y, Nana-Sinkam SP, Lee LJ. MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm. 2011;8(4): 1381-9.
54. Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther. 2011;10(8): 1470-80.
55. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17(2): 193-9.
56. Zenz T, Mohr J, Eldering E, Kater AP, Buhler A, Kienle D, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood. 2009;113(16): 3801-8.
57. ClinicalTrials. gov. http://clinicaltrials. gov/ct2/show/NCT01829971?term=mirna+therapeutics&rank=1. 2013.
58. Bader AG. miR-34-a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3: 120.
59. Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med. 2010;16(8): 909-14.
60. Zhang M, Zhou X, Wang B, Yung BC, Lee LJ, Ghoshal K et al. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. J Control Release. 2013;168: 251-61.
61. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther. 2010;18(9): 1650-6.
62. Liu XQ, Song WJ, Sun TM, Zhang PZ, Wang J. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol Pharm. 2011;8(1): 250-9.
63. Scientific B. http://www. biooscientific. com/Default. aspx. 2013.
64. Craig VJ, Tzankov A, Flori M, Schmid CA, Bader AG, Muller A. Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo. Leukemia. 2012;26(11): 2421-4.
65. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010;70(14): 5923-30.
66. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther. 2011;19(6): 1116-22.
67. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17(2): 211-5.
68. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol. 2008;18(10): 505-16.
69. Rodl W, Schaffert D, Wagner E, Ogris M. Synthesis of polyethylenimine-based nanocarriers for systemic tumor targeting of nucleic acids. Methods Mol Biol. 2013;948: 105-20.
70. Calarco A, Bosetti M, Margarucci S, Fusaro L, Nicoli E, Petillo O, et al. The genotoxicity of PEI-based nanoparticles is reduced by acetylation of polyethylenimine amines in human primary cells. Toxicol Lett. 2013;218(1): 10-7.
71. Chiou GY, Cherng JY, Hsu HS, Wang ML, Tsai CM, Lu KH, et al. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J Control Release. 2012;159(2): 240-50.
72. Pun SH, Bellocq NC, Liu A, Jensen G, Machemer T, Quijano E, et al. Cyclodextrin-modified polyethylenimine polymers for gene delivery. Bioconjug Chem. 2004;15(4): 831-40.
73. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010;328(5981): 1031-5.
74. Hu QL, Jiang QY, Jin X, Shen J, Wang K, Li YB, et al. Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials. 2013;34(9): 2265-76.
75. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev. 2005;57(15): 2215-37.
76. Ren Y, Kang CS, Yuan XB, Zhou X, Xu P, Han L, et al. Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed. 2010;21(3): 303-14.
77. Papasani MR, Wang G, Hill RA. Gold nanoparticles: the importance of physiological principles to devise strategies for targeted drug delivery. Nanomedicine. 2012;8(6): 804-14.
78. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: a microscopic overview. Langmuir. 2005;21(23): 10644-54.
79. Daniel MC, Astruc D. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology. Chem Rev. 2004;104(1): 293-346.
80. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AK, Han MS, Mirkin CA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science. 2006;312(5776): 1027-30.
81. Ghosh R, Singh LC, Shohet JM, Gunaratne PH. A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells. Biomaterials. 2013;34(3): 807-16.
82. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A. 2012;109(26): E1695-704.
83. Cheng CJ, Saltzman WM. Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing. Mol Pharm. 2012;9(5): 1481-8.
84. Barbe C, Bartlett J, Kong LG, Finnie K, Lin HQ, Larkin M, et al. Silica particles: a novel drug-delivery system. Adv Mater. 2004;16(21): 1959-66.
85. Tivnan A, Orr WS, Gubala V, Nooney R, Williams DE, McDonagh C, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One. 2012;7(5): e38129.
86. Kim JH, Yeom JH, Ko JJ, Han MS, Lee K, Na SY, et al. Effective delivery of anti-miRNA DNA oligonucleotides by functionalized gold nanoparticles. J Biotechnol. 2011;155(3): 287-92.
87. Kim JK, Choi KJ, Lee M, Jo MH, Kim S. Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials. 2012;33(1): 207-17.